(redirected from Aromatase inhibitors)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.
Related to Aromatase inhibitors: tamoxifen
See: deterrent
References in periodicals archive ?
Aromatase inhibitors are usually given to post-menopausal women, and prevent oestrogen from being produced in other tissues.
Hormone therapies have been established which inhibit ER signaling including Selective Estrogen Receptor Modulators (SERM) such as tamoxifen, selective estrogen receptor down-regulators (SERD) such as fulvestrant, and aromatase inhibitors such as letrozole, which dereases estrogen synthesis.
The SOFT trial included 3,066 women randomized to receive tamoxifen, tamoxifen with ovarian suppression, or an aromatase inhibitor with ovarian suppression.
The third-generation non-steroidal aromatase inhibitors: a review of their clinical benets in the second-line hormonal treatment of advanced breast cancer.
The 10-year death rate was 12.1% with aromatase inhibitors, versus 14.2% with tamoxifen.
It found that aromatase inhibitors saved more lives than tamoxifen.
SAN DIEGO -- The aromatase inhibitor letrozole didn't help boys with short stature grow taller, but it did boost their testosterone to concerning levels in a small study at Children's Hospital Los Angeles.
Aromatase inhibitors in women with clomiphene resistance: a randomized double blind placebo controlled trial.
SAN ANTONIO -- Adjuvant aromatase inhibitor therapy in postmenopausal breast cancer survivors was associated with an increased risk of incident nonischemic cardiovascular disease, compared with tamoxifen users in a large prospective study.
Rather most potent estrogen blockers and aromatase inhibitors are reported to occur naturally as Chrysin (5'7-Dihydroxyisoflavone) a flavonoid from blue passion flower and White Button Mushrooms with great real life results having therapeutic values [42].
Aromatase inhibitors are used in the treatment of post-menopausal women with receptor-positive breast malignancies in both metastatic and adjuvant settings.
"Raloxifene may increase the risk of blood clots, but has not been proven to do so." There is some evidence aromatase inhibitors also carry side effects--these drugs have most notably been associated with bone loss--but the Lancet study showed only an insignificant elevation in fractures compared with placebo (9 percent versus 8 percent).